<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214291</url>
  </required_header>
  <id_info>
    <org_study_id>G300213</org_study_id>
    <nct_id>NCT01214291</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer</brief_title>
  <acronym>TREAT2</acronym>
  <official_title>Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Toremifene Citrate is effective in reducing&#xD;
      the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation&#xD;
      Therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    cost of conducting the study and increased burden on the clinical trial professionals make it&#xD;
    impossible for us to proceed with the development of the drug.&#xD;
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Risk of Bone Fracture Occurrences</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene</intervention_name>
    <description>Toremifene 80mg daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  give voluntary signed informed consent&#xD;
&#xD;
          -  have histologically documented prostate cancer&#xD;
&#xD;
          -  have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa&#xD;
             for preceeding 12 months&#xD;
&#xD;
          -  expected to continue LHRHa therapy uninterrupted for the next 12 months&#xD;
&#xD;
          -  have total testosterone levels less than 50 ng/dL&#xD;
&#xD;
          -  Have BMD of lumbar spine or femoral neck at or below the BMD thresholds&#xD;
&#xD;
          -  have a Zubrod performance status &lt;or equal to 1&#xD;
&#xD;
          -  subject weight &lt;300 lbs(&lt;136 kg)&#xD;
&#xD;
          -  agree to complete a daily diary of medication intake&#xD;
&#xD;
          -  agree not to take excluded medications throughout the trial&#xD;
&#xD;
          -  agree to use an effective method of contraception&#xD;
&#xD;
          -  have adequate bone marrow, liver and renal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently or previously exposed&#xD;
&#xD;
          -  within the past 5 years to intravenous bisphosphonates, strontium ranelate or&#xD;
             Denosumab&#xD;
&#xD;
          -  for more than 3 years to oral bisphosphonates&#xD;
&#xD;
          -  within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone,&#xD;
             SERMs, calcitonin, calcitriol or oral gluccorticoids&#xD;
&#xD;
          -  have any disease or condition that would preclude an accurate evaluation of&#xD;
             radiographs of the thoracic or lumbar spine&#xD;
&#xD;
          -  have &lt;8 evaluable vertebrae&#xD;
&#xD;
          -  have a BMD T score &lt;-4 at the lumbar spine or total hip or femoral neck&#xD;
&#xD;
          -  have any history of other carcinomas within the last 5 years&#xD;
&#xD;
          -  Serum PSA &gt; 5ng/mL at baseline under ADT&#xD;
&#xD;
          -  have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid&#xD;
             arthritis&#xD;
&#xD;
          -  have active uncontrolled systemic viral, bacterial or fungal infections&#xD;
&#xD;
          -  have a clinically significant concurrent illness or psychological, familial,&#xD;
             sociological, geograhical or other condition that would not permit adequate follow-up&#xD;
             and compliance&#xD;
&#xD;
          -  received treatment with other investigational agents within 30 days&#xD;
&#xD;
          -  taking finasteride, dutasteride, danazol or testosterone like substances&#xD;
&#xD;
          -  taking herbal medicines or dietary supplements&#xD;
&#xD;
          -  have a history of thromboembolic disease including DVT or pulmonary embolus&#xD;
&#xD;
          -  have a QTcF of &gt; or equal to 450 msec or congenital or acquired QTc prolongation&#xD;
&#xD;
          -  have HIV&#xD;
&#xD;
          -  calcicum urolithiasis prohibiting the use of vitamin D&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Steiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>GTx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fractures</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

